Post-viral idiopathic purpura fulminans is associated with inherited thrombophilia and anti-cardiolipin antibodies

Autor: A. Theron, S. Ayadi, E. Boissier, O. Dautremay, J.-F. Schved, N. Sirvent, I. Diaz, G. Captier, C. Biron-Andreani, E. Jeziorski

Publikováno v: Frontiers in Pediatrics, Vol 11 (2023)

IntroductionIdiopathic purpura fulminans (IPF) is a rare and severe coagulation disorder, associated with transient anti-protein S (anti-PS) antibodies in the context of post-viral infection such as varicella. Anti-protein S antibodies are frequently

Externí odkaz: https://doaj.org/article/cbb0945dbbd645088b693c2364a9a8e3

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

Autor: Guy Young, Doris Quon, Janna M. Journeycake, Ismail Haroon Mitha, Thomas A. Wilkinson, Ahmad Al-Sabbagh, Johnny Mahlangu, Alok Srivastava, Philippe de Moerloose, Giancarlo Castaman, Craig M. Kessler, Kateryna V. Vilchevska, Michael Recht, Cédric Hermans, W. Allan Alexander, Michael U. Callaghan, J.-F. Schved, Santiago Bonanad Boix, James V. Luck, Oleksandra Stasyshyn, Wolfgang Miesbach, Robert F. Sidonio, Michael Wang, Amy D. Shapiro, Miguel A. Escobar, Claude Negrier, Jonathan M. Ducore, Christopher Macie, Daniel Bonzo, Cindy A. Leissinger

Publikováno v: HAEMOPHILIA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Haemophilia, Vol. 27, no. 6, p. 921-931 (2021)

Introduction Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460af57ed40fc47782a37557cb179f76
https://doi.org/10.1111/hae.14419

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antivitaminiques K, anticoagulants oraux directs : où est la vérité ?

Autor: J.-F. Schved, J.-P. Laroche

Publikováno v: Journal des Maladies Vasculaires. 41:383-388

Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are now in competition. The companies are trying to replace VKA by DOACs, totally or at least greatly VKA should VKA disappear in favor of DOACs? There are still many questions about

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d60983bb690a0ff7e5eda3e0fedc0748
https://doi.org/10.1016/j.jmv.2016.10.002

Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?

Autor: J.-F. Schved

Publikováno v: Transfusion Clinique et Biologique. 22:85-89

Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a8dec84ed3260edd81aa41971675356
https://doi.org/10.1016/j.tracli.2015.03.006